Drug application
ONIVYDE (IRINOTECAN HYDROCHLORIDE)
Drugs@FDA NDA 207793 · IPSEN
Key facts
| Drug name | ONIVYDE |
|---|---|
| Active ingredients | IRINOTECAN HYDROCHLORIDE |
| Application type | NDA |
| Application number | 207793 |
| Company | IPSEN |
| Dosage forms | INJECTABLE, LIPOSOMAL, INTRAVENOUS |
| Strength | EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) |
| Marketing status | Prescription |
| Reference listed drug | Yes |
| Latest submission class | Type 5 - New Formulation or New Manufacturer |
| Latest submission status date | Oct 22, 2015 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: